AbbVie (ABBV) Q1 FY2024 earnings: revenue $12.3 billion, up 0.7% on the year
AbbVie Inc. (ABBV) reported revenue of $12.3 billion for Q1 FY2024, the quarter ended 31 March 2024, up 0.7% on the same quarter a year earlier. Net income was $1.4 billion, up 472.8% on the year, and diluted earnings per share $0.77. The figures are the company's own, from the 10-Q it filed with the SEC on 3 May 2024.
Revenue
$12.3 billion
+0.7% on the year · -13.9% on the quarter
Q2 FY2022Q1 FY2024
Operating margin
22.7%
22.6% a year earlier
Q2 FY2022Q1 FY2024
Net income
$1.4 billion
+472.8% on the year · +66.5% on the quarter
Q2 FY2022Q1 FY2024
Diluted EPS
$0.77
+492.3% on the year · +67.4% on the quarter
Q2 FY2022Q1 FY2024
this quarterthe same quarter a year earlierHover a bar for its figure.
Income statement (profit and loss)
$ million
Q1 FY2024
Q4 FY2023
Q1 FY2023
On the quarter
On the year
Last 8 quarters
Revenue
12,310
14,301
12,225
-13.9%
+0.7%
Cost of revenue
4,094
5,704
3,986
-28.2%
+2.7%
Gross profit
8,216
8,597
8,239
-4.4%
-0.3%
Gross margin
66.7%
60.1%
67.4%
Research and development
1,939
1,927
2,292
+0.6%
-15.4%
Selling, general and administrative
3,315
3,193
3,039
+3.8%
+9.1%
Operating income
2,798
3,195
2,768
-12.4%
+1.1%
Operating margin
22.7%
22.3%
22.6%
Interest expense
660
564
553
+17.0%
+19.3%
Pre-tax income
1,755
1,212
475
+44.8%
+269.5%
Income tax
383
388
234
-1.3%
+63.7%
Effective tax rate
21.8%
32.0%
49.3%
Net income
1,369
822
239
+66.5%
+472.8%
Net margin
11.1%
5.7%
2.0%
Diluted EPS
$0.77
$0.46
$0.13
+67.4%
+492.3%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q1 FY2024
Q4 FY2023
Q1 FY2023
On the quarter
On the year
Last 8 quarters
Operating cash flow
4,040
4,753
4,193
-15.0%
-3.6%
Capital expenditure
193
205
175
-5.9%
+10.3%
Free cash flow
3,847
4,548
4,018
-15.4%
-4.3%
Free cash flow margin
31.3%
31.8%
32.9%
Cash from investing
-9,588
-800
-499
Cash from financing
10,819
-4,449
-6,192
Depreciation and amortisation
2,074
2,085
2,127
-0.5%
-2.5%
Share-based compensation
348
125
313
+178.4%
+11.2%
Buybacks
1,324
3.0
1,955
+44,033.3%
-32.3%
Dividends paid
2,772
2,626
2,661
+5.6%
+4.2%
Dividend per share
$1.55
$1.55
$1.48
0.0%
+4.7%
Diluted shares, weighted
1,773m
n/a
1,776m
-0.2%
Shares outstanding at period end
1,766m
1,766m
1,764m
-0.0%
+0.1%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q1 FY2024
Q4 FY2023
Q1 FY2023
On the quarter
On the year
Last 8 quarters
Shareholders' equity
8,007
10,360
13,274
-22.7%
-39.7%
Non-controlling interest
40.0
37.0
29.0
+8.1%
+37.9%
Short-term borrowings
n/a
0.0
n/a
Debt
74,001
59,245
62,093
+24.9%
+19.2%
Operating lease liabilities
n/a
735
n/a
Finance lease liabilities
n/a
27.0
n/a
Other liabilities
66,826
64,307
59,148
+3.9%
+13.0%
Total liabilities and equity
148,874
134,711
134,544
+10.5%
+10.7%
Fixed assets
4,980
4,989
4,931
-0.2%
+1.0%
Goodwill
33,426
32,293
32,220
+3.5%
+3.7%
Intangible assets
62,225
55,610
64,848
+11.9%
-4.0%
Investments
307
306
268
+0.3%
+14.6%
Cash and equivalents
18,067
12,814
6,711
+41.0%
+169.2%
Receivables
11,949
11,155
11,473
+7.1%
+4.1%
Inventory
4,245
4,099
3,833
+3.6%
+10.7%
Other assets
13,675
13,445
10,260
+1.7%
+33.3%
Total assets
148,874
134,711
134,544
+10.5%
+10.7%
Questions
What was AbbVie's revenue in Q1 FY2024?
AbbVie (ABBV) reported revenue of $12.3 billion for Q1 FY2024, the quarter ended 31 March 2024, up 0.7% on the same quarter a year earlier.
How much did AbbVie earn in Q1 FY2024?
Net income for Q1 FY2024 was $1.4 billion, up 472.8% on the year, and diluted earnings per share $0.77.
When did AbbVie report Q1 FY2024 results?
AbbVie filed its 10-Q for the quarter ended 31 March 2024 with the SEC on 3 May 2024.
Each quarter as filed, linked to its filing. Read moreMoney is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 31 March 2024, filed 3 May 2024: the filing.